title: PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis

summary: The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.

primary_purpose: Prevention

ReferenceCitation: Ovbiagele B, Bath PM, Cotton D, Sha N, Diener HC; PRoFESS Investigators. Low glomerular filtration rate, recurrent stroke risk, and effect of renin-angiotensin system modulation. Stroke. 2013 Nov;44(11):3223-5. doi: 10.1161/STROKEAHA.113.002463. Epub 2013 Aug 29.

ReferenceCitation: Böhm M, Cotton D, Foster L, Custodis F, Laufs U, Sacco R, Bath PM, Yusuf S, Diener HC. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J. 2012 Nov;33(22):2804-12. doi: 10.1093/eurheartj/ehs250. Epub 2012 Aug 26.

ReferenceCitation: Weber R, Weimar C, Blatchford J, Hermansson K, Wanke I, Möller-Hartmann C, Gizewski ER, Forsting M, Demchuk AM, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. Stroke. 2012 Sep;43(9):2336-42. Epub 2012 Jun 26.

ReferenceCitation: Weber R, Weimar C, Wanke I, Möller-Hartmann C, Gizewski ER, Blatchford J, Hermansson K, Demchuk AM, Forsting M, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke. 2012 Feb;43(2):350-5. doi: 10.1161/STROKEAHA.111.631739. Epub 2012 Jan 19.

ReferenceCitation: Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM; PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011 Nov 16;306(19):2137-44. doi: 10.1001/jama.2011.1650.

ReferenceCitation: Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008 Oct;7(10):875-84. doi: 10.1016/S1474-4422(08)70198-4. Epub 2008 Aug 29. Erratum in: Lancet Neurol. 2008 Nov;7(11):985.

ReferenceCitation: Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008 Sep 18;359(12):1225-37. doi: 10.1056/NEJMoa0804593. Epub 2008 Aug 27.

ReferenceCitation: Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008 Sep 18;359(12):1238-51. doi: 10.1056/NEJMoa0805002. Epub 2008 Aug 27.

location_country:
Spain
Italy
United Kingdom
Ukraine
El Salvador
United States
Belgium
Japan
South Africa
Hong Kong
Portugal
Austria
Australia
Russian Federation
Argentina
India
Israel
Turkey
Mexico
Norway
Malaysia
Singapore
Sweden
Brazil
Canada
China
Germany
Denmark
Taiwan
Greece
Ireland
Finland
Thailand
Korea, Republic of
France
Netherlands

location_facility: 9.159.1172 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2516 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1011 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1547 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1063 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1190 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1368 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2392 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2086 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1040 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1374 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1165 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1024 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2385 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2500 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1731 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1201 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2519 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2246 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1956 TweeSteden Ziekenhuis Tilburg

location_facility: 9.159.2724 Rambam Medical Center, Tel-Aviv Medical

location_facility: 9.159.1682 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2084 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1135 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1175 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1037 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1147 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1137 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1732 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2942 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1721 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2706 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2492 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2632 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1068 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1202 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2612 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2937 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1865 Ospedale Regionale "S. Salvatore"

location_facility: 9.159.1639 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2970 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2952 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2945 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1082 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1851 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1640 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2209 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1217 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2629 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1162 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2283 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2951 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1001 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1181 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2628 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1370 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1718 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1852 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1736 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2213 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1712 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1041 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1096 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2490 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2091 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1179 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2253 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2943 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1043 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2308 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2039 Centro Hospitalar e Universitário de Coimbra, EPE

location_facility: 9.159.1088 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2060 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2484 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1826 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1048 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2935 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1723 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2251 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1174 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1714 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1679 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2948 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2934 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1029 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2215 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1356 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2503 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2284 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1113 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2305 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2108 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1199 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2517 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2621 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2216 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1211 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1635 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2620 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1021 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1596 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2505 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2765 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1007 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2110 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1730 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2115 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1158 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2302 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1118 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2966 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2617 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1054 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2936 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1681 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1074 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2622 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1051 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2288 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2506 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2294 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2498 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1383 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2181 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2178 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2614 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2964 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2502 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2301 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2058 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2853 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2499 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1631 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1873 Istituto Scientifico "S. Luca"

location_facility: 9.159.2703 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2953 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1189 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2828 Dkuz Eylul Universitesi Tip Fakultesi Noroloji A.B.D.

location_facility: 9.159.1098 Community Healthcare Clinic Westhill Medical Specialists

location_facility: 9.159.1545 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1164 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2450 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2949 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1553 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2496 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1391 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1107 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2120 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1200 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2175 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1355 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2497 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1141 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2290 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1196 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1100 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2449 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2055 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1358 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2222 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1715 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2830 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2092 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1733 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2117 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2608 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2956 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1066 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2085 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1055 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1638 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1159 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1075 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1160 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1145 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1122 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2098 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2939 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2488 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2613 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2486 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2298 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1376 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1551 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1128 St. Luke's Hospital MABSI Research

location_facility: 9.159.1554 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2118 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2295 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2511 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1150 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1719 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1207 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2101 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1084 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2826 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2611 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2827 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1709 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1594 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2105 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1125 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2103 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1061 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1876 Azienda Ospedaliera di Padova -Policlinico Universitario

location_facility: 9.159.1140 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2304 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2616 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1154 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2214 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1006 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1052 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2179 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2388 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1387 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1076 North Shore University Hospital

location_facility: 9.159.1734 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1342 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2107 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1722 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2207 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2947 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2106 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1094 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1359 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1659 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1365 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1102 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2963 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2631 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2447 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1548 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2061 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2962 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1392 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1204 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1044 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1095 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1056 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1520 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1333 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1010 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2391 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2176 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1019 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1108 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1039 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1031 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1081 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1013 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2829 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2027 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1868 Ospedale "S. Maria di Loreto Mare"

location_facility: 9.159.2799 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1544 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1078 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1176 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2446 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1057 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1134 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2451 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1099 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1188 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1396 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2093 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2513 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2627 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1070 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2252 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2247 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1871 Azienda Ospedaliera "Careggi"

location_facility: 9.159.1060 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1634 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2205 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2507 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1869 Università degli Studi di Genova

location_facility: 9.159.2379 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1139 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1038 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1171 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2489 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1825 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2969 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2083 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2177 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1085 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1708 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2080 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1116 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1177 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1593 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2386 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2515 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1357 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2933 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2059 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1025 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1655 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1728 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2512 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2243 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2798 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1009 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2723 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1517 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2088 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1819 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2119 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2972 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2959 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1121 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1191 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1335 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2487 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2286 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1022 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2212 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1155 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1369 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2615 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2946 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1192 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1117 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1552 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2180 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2954 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1023 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1361 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1132 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2941 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1148 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2494 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1008 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1395 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2111 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2501 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1053 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2825 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2041 Centro Hospitalar de Lisboa Norte

location_facility: 9.159.1077 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2514 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1546 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2797 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1163 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1595 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2224 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2443 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2713 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1110 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1367 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1515 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1169 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1717 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2292 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2306 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1203 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1035 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1195 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1683 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1120 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2289 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1071 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1713 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1519 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1379 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2444 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2448 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1381 Ottawa Hospital General Campus

location_facility: 9.159.2961 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1131 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1384 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1062 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2254 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1016 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2100 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1820 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2112 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1194 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2296 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1716 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1380 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2116 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1373 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2485 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1106 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2495 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1087 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1032 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1334 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1385 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2099 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2605 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1072 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1127 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2287 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2483 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1111 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1205 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1138 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1371 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1521 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2297 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2211 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1729 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1033 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1214 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1332 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1684 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1030 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2285 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1877 Azienda Ospedaliera Umberto I

location_facility: 9.159.1045 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1170 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2618 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2307 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2293 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1555 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1186 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1151 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1126 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2081 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1518 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1089 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2210 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2705 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1143 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2389 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1152 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2625 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1597 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2603 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1130 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2204 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1047 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2249 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1591 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1213 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1724 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1119 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1091 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2250 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2095 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1549 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2291 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2609 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2299 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1017 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2029 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1027 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1657 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1727 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1821 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1208 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1065 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1711 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1086 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2248 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2955 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1637 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1739 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2518 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1153 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1394 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1166 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1049 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1632 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1003 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1360 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1064 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1720 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2102 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1710 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2089 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1633 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2707 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1133 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1101 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2109 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2800 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2382 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2624 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1149 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1218 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1012 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1219 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2244 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1083 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1187 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2944 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2300 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1212 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2973 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1680 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1372 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1331 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1636 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1656 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1146 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1142 Saint Luke's-Roosevelt Hospital

location_facility: 9.159.2704 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1209 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2056 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1079 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1707 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1173 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1216 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1112 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1388 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1005 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2958 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1658 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2113 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1183 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2491 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1114 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2607 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1136 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1036 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1382 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2510 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1097 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2028 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2208 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1002 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1737 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1210 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1004 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1685 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2604 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2957 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2206 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1198 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2303 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1185 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1020 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1092 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2203 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1364 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2606 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1864 Azienda Ospedaliera "S. Giovanni Battista"

location_facility: 9.159.1178 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2521 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1390 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2225 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2245 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2380 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1592 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1080 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1516 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1180 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2801 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1725 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1090 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2831 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2967 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2223 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2114 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1069 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1726 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2965 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2079 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2452 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2390 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2445 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2626 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2087 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1824 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2610 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2968 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2938 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1197 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1377 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2094 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1867 Presidio Ospedaliero G.Jazzolino

location_facility: 9.159.2504 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1735 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1375 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2509 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1215 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1220 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2493 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2714 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1393 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1363 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1184 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1366 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1878 Azienda Ospedaliera "Santo Maria"

location_facility: 9.159.2097 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2082 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1042 Neurology Consultants of Burlington County

location_facility: 9.159.1104 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1556 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1046 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1378 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1182 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2387 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1058 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2623 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1362 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1123 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1059 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1336 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1389 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2104 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2940 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1144 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2057 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2520 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2950 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1875 Università degli Studi di Ancona

location_facility: 9.159.1156 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2090 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1738 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1018 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1014 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1550 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1206 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2630 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1543 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2971 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2384 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2869 Complexo Hospitalar Universitario Prof Edgard Santos

location_facility: 9.159.2619 Boehringer Ingelheim Investigational Site


title: A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks

summary: Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients

status: Terminated

study_type: Interventional

design_allocation: Randomized

primary_purpose: Treatment

enrollment_type: Actual

lead_sponsor: Boehringer Ingelheim

location_country:
Poland
Brazil
Romania
Spain
United Kingdom
Russian Federation
Australia
Mexico
Argentina
Canada
Thailand
France
Colombia
Bahamas
Germany

location_facility: UNIFESP/ Hospital São Paulo- Univers. Federal de São Paulo

location_facility: Unidade de Pesquisa Clínica (UPC) - AIDS

location_facility: Matei Bals Institute of Infectious Diseases

location_facility: Sunnybrook & Woman's College Health Science Centre

location_facility: Hospital Geral de Nova Iguaçu - Ministério da Saúde

location_facility: I.I. Emilio Ribas - Moléstias Infecciosas

location_facility: Boehringer Ingelheim Investigational Site

location_facility: Montreal General Hospital - McGill University Health Centre

location_facility: Centro de Referência e Treinamento - DST/AIDS

location_facility: Ciutat Sanitaria Universitaria de Bellvitge

location_facility: Hospital do Servidor Público Estadual de São Paulo

location_facility: Canadian Immunodeficiency Research Collaborative Inc.

location_facility: Instituto de Crianca / Hospital das Clínicas-FMUSP

location_facility: Montreal Chest Institute, McGill University Health Centre

location_facility: Universidade Federal da Bahia-Unidade Docente Assistencial d

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Unknown


title: An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo

summary: The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.

status: Completed

study_completion_date_type: Actual

ipd_sharing: Yes

ipd_sharing_description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

lead_sponsor: GlaxoSmithKline

location_country:
Poland
Netherlands
Canada
India
Costa Rica
France
Peru
Mexico
South Africa
Germany

status_simplified: Completed


title: Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer

acronym: OPUS

summary: This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor (EGFR)-expressing mCRC.

ReferenceType: result

ReferenceCitation: Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10;27(5):663-71. doi: 10.1200/JCO.2008.20.8397. Epub 2008 Dec 29.

ReferenceCitation: Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011 Jul;22(7):1535-1546. doi: 10.1093/annonc/mdq632. Epub 2011 Jan 12.

lead_sponsor: Merck KGaA, Darmstadt, Germany

location_country:
Poland
Portugal
Romania
Spain
Greece
Austria
Italy
Russian Federation
Ukraine
France
Israel
Belgium
Germany

intervention_type: Biological


type: EudraCT Number

title: A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B

summary: The primary objectives of this study are to compare the efficacy, safety, and tolerability of tenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B. Participants will receive TDF or ADV for 48 weeks (double-blind). After 48 weeks, eligible participants switched to open-label TDF for up to 480 weeks.

study_start_date_type: Actual

ReferenceCitation: Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014 Feb;59(2):434-42.

ReferenceCitation: Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.

ReferenceCitation: Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013 Aug;58(2):505-13. doi: 10.1002/hep.26277. Epub 2013 May 3.

ReferenceCitation: Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, Trinh H, Flaherty JF, Kitrinos KM, Dinh P, Charuworn P, Subramanian GM, Gane E. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci. 2015 Jan;60(1):260-8. doi: 10.1007/s10620-014-3336-7. Epub 2014 Sep 2.

ReferenceCitation: Fung S, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, Jacobson IM, Yee LJ, Dinh P, Martins EB, Flaherty JF, Kitrinos KM, Dusheiko G, Trinh H, Flisiak R, Rustgi VK, Buti M, Marcellin P. Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). Liver Int. 2015 Feb;35(2):422-8. doi: 10.1111/liv.12694. Epub 2014 Oct 28.

ReferenceCitation: Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Subramanian GM, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Heathcote EJ. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol. 2014 Dec;61(6):1228-37. doi: 10.1016/j.jhep.2014.07.019. Epub 2014 Jul 18.

ReferenceCitation: Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P, Bornstein JD, Mani Subramanian G, Janssen HL, George J, Marcellin P. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015 Apr;9(2):243-50. doi: 10.1007/s12072-015-9614-4. Epub 2015 Mar 13.

ReferenceCitation: Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015 May;60(5):1457-64. doi: 10.1007/s10620-014-3486-7. Epub 2014 Dec 23.

ReferenceCitation: Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, Kitrinos KM, Marcellin P, Gane EJ. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017 Jan;24(1):68-74. doi: 10.1111/jvh.12613. Epub 2016 Sep 23.

ReferenceCitation: Corsa A, Liu Y, Flaherty JF, Marcellin P, Miller M, Kitrinos KM. No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg+ and HBeAg- Patients With Chronic Hepatitis B (CHB) After Eight Years of Treatment [Abstract 1707]. The 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting (AASLD); 2014 08-10 November; Boston MA.

ReferenceCitation: Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gurel S, et al. Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials [Abstract]. 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2014 November 7-11; Boston, MA.

ReferenceCitation: Gane EJ, Marcellin P, Sievert W, Trinh HN, Shiffman ML, Washington MK, et al. Five years of Treatment with Tenofovir DF for Chronic Hepatitis B Infection in Asian Patients is Associated with Sustained Viral Suppression and Significant Regression of Histological Fibrosis and Cirrhosis [Poster Number 1429]. 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 2011 November 4-8; San Francisco, California.

ReferenceType: derived

ReferenceCitation: Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019 Oct;39(10):1868-1875. doi: 10.1111/liv.14155. Epub 2019 Jul 10.

ReferenceCitation: Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20.

ReferenceCitation: Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, McHutchison JG, Younossi Z, Marcellin P, Patel K. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1087-1094.e2. doi: 10.1016/j.cgh.2017.01.032. Epub 2017 Feb 12.

ReferenceCitation: Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut. 2017 Nov;66(11):2013-2023. doi: 10.1136/gutjnl-2015-309300. Epub 2016 Aug 17.

ReferenceCitation: Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. World J Gastroenterol. 2015 May 14;21(18):5524-31. doi: 10.3748/wjg.v21.i18.5524.

ReferenceCitation: Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011 Jan;140(1):132-43. doi: 10.1053/j.gastro.2010.10.011. Epub 2010 Oct 16.

ReferenceCitation: Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.

lead_sponsor: Gilead Sciences

location_country:
Poland
Spain
Greece
Italy
Australia
Netherlands
Canada
Czech Republic
New Zealand
United Kingdom
United States
France
Turkey
Germany
Bulgaria


title: SYNTAX Study: SYNergy Between PCI With TAXUS and Cardiac Surgery

acronym: SYNTAX

summary: The SYNTAX trial is designed to determine the best treatment for patients with complex coronary disease (blocked or narrowed arteries in both the right and left sides of the heart) by randomizing patients to receive either percutaneous coronary intervention (PCI) with polymer-based paclitaxel-eluting TAXUS stents or to coronary artery bypass surgery (CABG).

status: Unknown status

study_completion_date_type: Anticipated

ReferenceCitation: Ono M, Serruys PW, Garg S, Kawashima H, Gao C, Hara H, Lunardi M, Wang R, O'Leary N, Wykrzykowska JJ, Piek JJ, Mack MJ, Holmes DR, Morice MC, Kappetein AP, Thuijs DJFM, Noack T, Mohr FW, Davierwala PM, Spertus JA, Cohen DJ, Onuma Y; SYNTAX Extended Survival Investigators. Effect of Patient-Reported Preprocedural Physical and Mental Health on 10-Year Mortality After Percutaneous or Surgical Coronary Revascularization. Circulation. 2022 Oct 25;146(17):1268-1280. doi: 10.1161/CIRCULATIONAHA.121.057021. Epub 2022 Jul 18.

ReferenceCitation: Ono M, Hara H, Gao C, Kawashima H, Wang R, O'Leary N, Wykrzykowska JJ, Piek JJ, Mack MJ, Holmes D, Morice MC, Head S, Kappetein AP, Noack T, Davierwala PM, Mohr FW, Garg S, Onuma Y, Serruys PW; SYNTAX Extended Survival Investigators. Mortality after multivessel revascularisation involving the proximal left anterior descending artery. Heart. 2022 Oct 28;108(22):1784-1791. doi: 10.1136/heartjnl-2022-320934.

ReferenceCitation: Ninomiya K, Serruys PW, Garg S, Gao C, Masuda S, Lunardi M, Lassen JF, Banning AP, Colombo A, Burzotta F, Morice MC, Mack MJ, Holmes DR, Davierwala PM, Thuijs DJFM, van Klaveren D, Onuma Y; SYNTAX Extended Survival Investigators. Predicted and Observed Mortality at 10 Years in Patients With Bifurcation Lesions in the SYNTAX Trial. JACC Cardiovasc Interv. 2022 Jun 27;15(12):1231-1242. doi: 10.1016/j.jcin.2022.04.025. Epub 2022 May 17.

ReferenceCitation: Takahashi K, Serruys PW, Fuster V, Farkouh ME, Spertus JA, Cohen DJ, Park SJ, Park DW, Ahn JM, Onuma Y, Kent DM, Steyerberg EW, van Klaveren D; SYNTAX, BEST, and FREEDOM Trial investigators. External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI. J Am Coll Cardiol. 2022 Apr 19;79(15):1458-1473. doi: 10.1016/j.jacc.2022.01.049.

ReferenceCitation: Kawashima H, Serruys PW, Hara H, Ono M, Gao C, Wang R, Garg S, Sharif F, de Winter RJ, Mack MJ, Holmes DR, Morice MC, Kappetein AP, Thuijs DJFM, Milojevic M, Noack T, Mohr FW, Davierwala PM, Onuma Y; SYNTAX Extended Survival Investigators. 10-Year All-Cause Mortality Following Percutaneous or Surgical Revascularization in Patients With Heavy Calcification. JACC Cardiovasc Interv. 2022 Jan 24;15(2):193-204. doi: 10.1016/j.jcin.2021.10.026. Epub 2021 Dec 29.

ReferenceCitation: Hara H, Kawashima H, Ono M, Takahashi K, Mack MJ, Holmes DR Jr, Morice MC, Davierwala PM, Mohr FW, Thuijs DJFM, Kappetein AP, O'Leary N, van Klaveren D, Onuma Y, Serruys PW. Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial. EuroIntervention. 2022 Apr 22;17(18):1477-1487. doi: 10.4244/EIJ-D-21-00415.

ReferenceCitation: Thuijs DJFM, Davierwala P, Milojevic M, Deo SV, Noack T, Kappetein AP, Serruys PW, Mohr FW, Morice MC, Mack MJ, Ståhle LEGE, Verberkmoes NJ, Holmes DR, Head SJ; SYNTAX Extended Survival Investigators. Long-term survival after coronary bypass surgery with multiple versus single arterial grafts. Eur J Cardiothorac Surg. 2022 Mar 24;61(4):925-933. doi: 10.1093/ejcts/ezab392.

ReferenceCitation: Wang R, Garg S, Gao C, Kawashima H, Ono M, Hara H, van Geuns RJ, Morice MC, Davierwala PM, Kappetein AP, Holmes DR, Wijns W, Tao L, Onuma Y, Serruys PW. Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease. Clin Res Cardiol. 2021 Oct;110(10):1680-1691. doi: 10.1007/s00392-021-01922-y. Epub 2021 Aug 25.

ReferenceCitation: Davierwala PM, Gao C, Thuijs DJFM, Wang R, Hara H, Ono M, Noack T, Garg S, O'leary N, Milojevic M, Kappetein AP, Morice MC, Mack MJ, van Geuns RJ, Holmes DR, Gaudino M, Taggart DP, Onuma Y, Mohr FW, Serruys PW; SYNTAX Extended Survival Investigators. Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease. Eur Heart J. 2022 Mar 31;43(13):1334-1344. doi: 10.1093/eurheartj/ehab537.

ReferenceCitation: Wang R, Serruys PW, Gao C, Hara H, Takahashi K, Ono M, Kawashima H, O'leary N, Holmes DR, Witkowski A, Curzen N, Burzotta F, James S, van Geuns RJ, Kappetein AP, Morel MA, Head SJ, Thuijs DJFM, Davierwala PM, O'Brien T, Fuster V, Garg S, Onuma Y. Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. Eur Heart J. 2021 Dec 28;43(1):56-67. doi: 10.1093/eurheartj/ehab441.

ReferenceCitation: Ono M, Kawashima H, Hara H, Mancone M, Mack MJ, Holmes DR, Morice MC, Kappetein AP, Thuijs DJFM, Noack T, Mohr FW, Davierwala PM, Onuma Y, Serruys PW; SYNTAX Extended Survival Investigators. Impact of major infections on 10-year mortality after revascularization in patients with complex coronary artery disease. Int J Cardiol. 2021 Oct 15;341:9-12. doi: 10.1016/j.ijcard.2021.08.013. Epub 2021 Aug 8.

ReferenceCitation: Kawashima H, Serruys PW, Ono M, Hara H, O'Leary N, Mack MJ, Holmes DR, Morice MC, Head SJ, Kappetein AP, Thuijs DJFM, Milojevic M, Noack T, Mohr FW, Davierwala PM, Sharif F, McEvoy JW, Onuma Y; SYNTAX Extended Survival Investigators. Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization. J Am Coll Cardiol. 2021 Jul 6;78(1):27-38. doi: 10.1016/j.jacc.2021.04.087.

ReferenceCitation: Ono M, Serruys PW, Hara H, Kawashima H, Gao C, Wang R, Takahashi K, O'Leary N, Wykrzykowska JJ, Sharif F, Piek JJ, Garg S, Mack MJ, Holmes DR, Morice MC, Head SJ, Kappetein AP, Thuijs DJFM, Noack T, Davierwala PM, Mohr FW, Cohen DJ, Onuma Y; SYNTAX Extended Survival Investigators. 10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease. J Am Coll Cardiol. 2021 Jun 8;77(22):2761-2773. doi: 10.1016/j.jacc.2021.04.016.

ReferenceCitation: Ono M, Kawashima H, Hara H, O'Leary N, Gao C, Wang R, Takahashi K, Wykrzykowska JJ, Piek JJ, Mack MJ, Holmes DR, Morice MC, Head SJ, Kappetein AP, Thuijs DJFM, Noack T, Friedrich MW, Davierwala PM, McEvoy JW, Onuma Y, Serruys PW. Impact of Body Composition Indices on Ten-year Mortality After Revascularization of Complex Coronary Artery Disease (From the Syntax Extended Survival Trial). Am J Cardiol. 2021 Jul 15;151:30-38. doi: 10.1016/j.amjcard.2021.04.008. Epub 2021 May 26.

ReferenceCitation: Takahashi K, Serruys PW, Gao C, Ono M, Wang R, Thuijs DJFM, Mack MJ, Curzen N, Mohr FW, Davierwala P, Milojevic M, Wykrzykowska JJ, de Winter RJ, Sharif F, Onuma Y, Head SJ, Kappetein AP, Morice MC, Holmes DR Jr; SYNTAX Extended Survival Study Investigators. Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study. Circulation. 2021 Jul 13;144(2):96-109. doi: 10.1161/CIRCULATIONAHA.120.046289. Epub 2021 May 20.

ReferenceCitation: Wang R, Tomaniak M, Takahashi K, Gao C, Kawashima H, Hara H, Ono M, van Klaveren D, van Geuns RJ, Morice MC, Davierwala PM, Mack MJ, Witkowski A, Curzen N, Berti S, Burzotta F, James S, Kappetein AP, Head SJ, Thuijs DJFM, Mohr FW, Holmes DR, Tao L, Onuma Y, Serruys PW. Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. Clin Res Cardiol. 2021 Jul;110(7):1083-1095. doi: 10.1007/s00392-021-01833-y. Epub 2021 Mar 12.

ReferenceCitation: Takahashi K, Thuijs DJFM, Gao C, Ono M, Holmes DR, Mack MJ, Morice MC, Mohr FW, Curzen N, Davierwala PM, Milojevic M, Dawkins KD, Wykrzykowska JJ, de Winter RJ, McEvoy JW, Onuma Y, Head SJ, Kappetein AP, Serruys PW; SYNTAX Extended Survival Study Investigators. Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization. Eur J Prev Cardiol. 2022 Mar 11;29(2):312-320. doi: 10.1093/eurjpc/zwaa089.

ReferenceCitation: Kawashima H, Takahashi K, Ono M, Hara H, Wang R, Gao C, Sharif F, Mack MJ, Holmes DR, Morice MC, Head SJ, Kappetein AP, Thuijs DJFM, Milojevic M, Noack T, Mohr FW, Davierwala PM, Serruys PW, Onuma Y; SYNTAX Extended Survival Investigators. Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions. J Am Coll Cardiol. 2021 Feb 9;77(5):529-540. doi: 10.1016/j.jacc.2020.11.055.

ReferenceCitation: Wang R, Takahashi K, Garg S, Thuijs DJFM, Kappetein AP, Mack MJ, Morice MC, Mohr FW, Curzen N, Davierwala P, Milojevic M, van Geuns RJ, Head SJ, Onuma Y, Holmes DR Jr, Serruys PW. Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study. Clin Res Cardiol. 2021 Oct;110(10):1543-1553. doi: 10.1007/s00392-020-01802-x. Epub 2021 Jan 30.

ReferenceCitation: Hara H, Serruys PW, Takahashi K, Kawashima H, Ono M, Gao C, Wang R, Mohr FW, Holmes DR, Davierwala PM, Head SJ, Thuijs DJFM, Milojevic M, Kappetein AP, Garg S, Onuma Y, Mack MJ; SYNTAX Extended Survival Investigators. Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization. J Am Coll Cardiol. 2020 Oct 6;76(14):1622-1639. doi: 10.1016/j.jacc.2020.08.009.

ReferenceCitation: Hara H, Takahashi K, van Klaveren D, Wang R, Garg S, Ono M, Kawashima H, Gao C, Mack M, Holmes DR, Morice MC, Head SJ, Kappetein AP, Thuijs DJFM, Onuma Y, Noack T, Mohr FW, Davierwala PM, Serruys PW; SYNTAX Extended Survival Investigators. Sex Differences in All-Cause Mortality in the Decade Following Complex Coronary Revascularization. J Am Coll Cardiol. 2020 Aug 25;76(8):889-899. doi: 10.1016/j.jacc.2020.06.066.

ReferenceCitation: Modolo R, Chichareon P, Kogame N, Dressler O, Crowley A, Ben-Yehuda O, Puskas J, Banning A, Taggart DP, Kappetein AP, Sabik JA, Onuma Y, Stone GW, Serruys PW. Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease. J Am Coll Cardiol. 2019 Apr 23;73(15):1877-1886. doi: 10.1016/j.jacc.2018.12.090.

ReferenceCitation: Milojevic M, Head SJ, Mack MJ, Mohr FW, Morice MC, Dawkins KD, Holmes DR Jr, Serruys PW, Kappetein AP. Influence of practice patterns on outcome among countries enrolled in the SYNTAX trial: 5-year results between percutaneous coronary intervention and coronary artery bypass grafting. Eur J Cardiothorac Surg. 2017 Sep 1;52(3):445-453. doi: 10.1093/ejcts/ezx104.

ReferenceCitation: Sotomi Y, Onuma Y, Cavalcante R, Ahn JM, Lee CW, van Klaveren D, de Winter RJ, Wykrzykowska JJ, Farooq V, Morice MC, Steyerberg EW, Park SJ, Serruys PW. Geographical Difference of the Interaction of Sex With Treatment Strategy in Patients With Multivessel Disease and Left Main Disease: A Meta-Analysis From SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery), PRECOMBAT (Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease), and BEST (Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease) Randomized Controlled Trials. Circ Cardiovasc Interv. 2017 May;10(5). pii: e005027. doi: 10.1161/CIRCINTERVENTIONS.117.005027.

ReferenceCitation: Abdallah MS, Wang K, Magnuson EA, Osnabrugge RL, Kappetein AP, Morice MC, Mohr FA, Serruys PW, Cohen DJ; SYNTAX Trial Investigators. Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. J Am Coll Cardiol. 2017 Apr 25;69(16):2039-2050. doi: 10.1016/j.jacc.2017.02.031.

ReferenceCitation: Cavalcante R, Sotomi Y, Zeng Y, Lee CW, Ahn JM, Collet C, Tenekecioglu E, Suwannasom P, Onuma Y, Park SJ, Serruys PW. Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery. Heart. 2017 Mar;103(6):428-433. doi: 10.1136/heartjnl-2016-309720. Epub 2016 Sep 20.

ReferenceCitation: Migliorini A, Valenti R, Parodi G, Vergara R, Buonamici P, Cerisano G, Carrabba N, Antoniucci D. Angiographic and Clinical Outcomes After Everolimus-Eluting Stenting for Unprotected Left Main Disease and High Anatomic Coronary Complexity. JACC Cardiovasc Interv. 2016 May 23;9(10):1001-7. doi: 10.1016/j.jcin.2016.02.016.

ReferenceCitation: Milojevic M, Head SJ, Parasca CA, Serruys PW, Mohr FW, Morice MC, Mack MJ, Ståhle E, Feldman TE, Dawkins KD, Colombo A, Kappetein AP, Holmes DR Jr. Causes of Death Following PCI Versus CABG in Complex CAD: 5-Year Follow-Up of SYNTAX. J Am Coll Cardiol. 2016 Jan 5;67(1):42-55. doi: 10.1016/j.jacc.2015.10.043.

ReferenceCitation: Osnabrugge RL, Magnuson EA, Serruys PW, Campos CM, Wang K, van Klaveren D, Farooq V, Abdallah MS, Li H, Vilain KA, Steyerberg EW, Morice MC, Dawkins KD, Mohr FW, Kappetein AP, Cohen DJ; SYNTAX trial investigators. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. Heart. 2015 Dec;101(24):1980-8. doi: 10.1136/heartjnl-2015-307578. Epub 2015 Nov 9.

ReferenceCitation: Parasca CA, Head SJ, Mohr FW, Mack MJ, Morice MC, Holmes DR Jr, Feldman TE, Colombo A, Dawkins KD, Serruys PW, Kappetein AP; SYNTAX Investigators. The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry. J Thorac Cardiovasc Surg. 2015 Sep;150(3):597-606.e2. doi: 10.1016/j.jtcvs.2015.05.010. Epub 2015 May 8.

ReferenceCitation: Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein AP, Feldman T, Stahle E, Escaned J, Banning AP, Gunn JP, Colombo A, Steyerberg EW, Mohr FW, Serruys PW. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. Circulation. 2015 Apr 7;131(14):1269-77. doi: 10.1161/CIRCULATIONAHA.114.013042. Epub 2015 Feb 24.

ReferenceCitation: Campos CM, Costa F, Garcia-Garcia HM, Bourantas C, Suwannasom P, Valgimigli M, Morel MA, Windecker S, Serruys PW. Anatomic characteristics and clinical implications of angiographic coronary thrombus: insights from a patient-level pooled analysis of SYNTAX, RESOLUTE, and LEADERS Trials. Circ Cardiovasc Interv. 2015 Apr;8(4). pii: e002279. doi: 10.1161/CIRCINTERVENTIONS.114.002279.

ReferenceCitation: Zhang YJ, Iqbal J, van Klaveren D, Campos CM, Holmes DR, Kappetein AP, Morice MC, Banning AP, Grech ED, Bourantas CV, Onuma Y, Garcia-Garcia HM, Mack MJ, Colombo A, Mohr FW, Steyerberg EW, Serruys PW. Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. J Am Coll Cardiol. 2015 Mar 24;65(11):1107-15. doi: 10.1016/j.jacc.2015.01.014.

ReferenceCitation: Cohen DJ, Osnabrugge RL, Magnuson EA, Wang K, Li H, Chinnakondepalli K, Pinto D, Abdallah MS, Vilain KA, Morice MC, Dawkins KD, Kappetein AP, Mohr FW, Serruys PW; SYNTAX Trial Investigators. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2014 Sep 30;130(14):1146-57. doi: 10.1161/CIRCULATIONAHA.114.009985. Epub 2014 Aug 1.

ReferenceCitation: Zhang YJ, Iqbal J, Campos CM, Klaveren DV, Bourantas CV, Dawkins KD, Banning AP, Escaned J, de Vries T, Morel MA, Farooq V, Onuma Y, Garcia-Garcia HM, Stone GW, Steyerberg EW, Mohr FW, Serruys PW. Prognostic value of site SYNTAX score and rationale for combining anatomic and clinical factors in decision making: insights from the SYNTAX trial. J Am Coll Cardiol. 2014 Aug 5;64(5):423-32. doi: 10.1016/j.jacc.2014.05.022.

ReferenceCitation: Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, Morice MC, Holmes DR Jr, Feldman TE, Ståhle E, Underwood P, Dawkins KD, Kappetein AP, Mohr FW. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014 Oct 21;35(40):2821-30. doi: 10.1093/eurheartj/ehu213. Epub 2014 May 21.

ReferenceCitation: Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR, Choi JW, Ruzyllo W, Religa G, Huang J, Roy K, Dawkins KD, Mohr F. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. Circulation. 2014 Jun 10;129(23):2388-94. doi: 10.1161/CIRCULATIONAHA.113.006689. Epub 2014 Apr 3.

ReferenceCitation: Vranckx P, Kalesan B, Stefanini GG, Farooq V, Onuma Y, Silber S, de Vries T, Jüni P, Serruys PW, Windecker S. Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. EuroIntervention. 2015 Jun;11(2):171-9. doi: 10.4244/EIJV11I2A31.

ReferenceCitation: Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, Ståhle E, Colombo A, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation. 2013 Jul 9;128(2):141-51. doi: 10.1161/CIRCULATIONAHA.113.001803. Epub 2013 Jun 13.

ReferenceCitation: Mack MJ, Head SJ, Holmes DR Jr, Ståhle E, Feldman TE, Colombo A, Morice MC, Unger F, Erglis A, Stoler R, Dawkins KD, Serruys PW, Mohr FW, Kappetein AP. Analysis of stroke occurring in the SYNTAX trial comparing coronary artery bypass surgery and percutaneous coronary intervention in the treatment of complex coronary artery disease. JACC Cardiovasc Interv. 2013 Apr;6(4):344-54. doi: 10.1016/j.jcin.2012.11.010. Epub 2013 Mar 20.

ReferenceCitation: Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, Kappetein AP, Colombo A, Holmes DR Jr, Mack M, Feldman T, Morice MC, Ståhle E, Onuma Y, Morel MA, Garcia-Garcia HM, van Es GA, Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013 Feb 23;381(9867):639-50. doi: 10.1016/S0140-6736(13)60108-7.

ReferenceCitation: Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013 Feb 23;381(9867):629-38. doi: 10.1016/S0140-6736(13)60141-5.

ReferenceCitation: Head SJ, Holmes DR Jr, Mack MJ, Serruys PW, Mohr FW, Morice MC, Colombo A, Kappetein AP; SYNTAX Investigators. Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. JACC Cardiovasc Interv. 2012 Jun;5(6):618-25. doi: 10.1016/j.jcin.2012.02.013.

ReferenceCitation: Serruys PW, Farooq V, Vranckx P, Girasis C, Brugaletta S, Garcia-Garcia HM, Holmes DR Jr, Kappetein AP, Mack MJ, Feldman T, Morice MC, Ståhle E, James S, Colombo A, Pereda P, Huang J, Morel MA, Van Es GA, Dawkins KD, Mohr FW, Steyerberg EW. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. JACC Cardiovasc Interv. 2012 Jun;5(6):606-17. doi: 10.1016/j.jcin.2012.03.016.

ReferenceCitation: Arnold SV, Magnuson EA, Wang K, Serruys PW, Kappetein AP, Mohr FW, Cohen DJ; SYNTAX Investigators. Do differences in repeat revascularization explain the antianginal benefits of bypass surgery versus percutaneous coronary intervention?: implications for future treatment comparisons. Circ Cardiovasc Qual Outcomes. 2012 May;5(3):267-75. doi: 10.1161/CIRCOUTCOMES.111.964585. Epub 2012 Apr 10.

ReferenceCitation: Morice MC, Feldman TE, Mack MJ, Ståhle E, Holmes DR, Colombo A, Morel MA, van den Brand M, Serruys PW, Mohr F, Carrié D, Fournial G, James S, Leadley K, Dawkins KD, Kappetein AP. Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS). EuroIntervention. 2011 Oct 30;7(6):670-9. doi: 10.4244/EIJV7I6A109.

ReferenceCitation: Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, den Heijer P, Vrakking MM, Wang K, Mahoney EM, Audi S, Leadley K, Dawkins KD, Kappetein AP; Synergy between PCI with Taxus and Cardiac Surgery Investigators. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med. 2011 Mar 17;364(11):1016-26. doi: 10.1056/NEJMoa1001508.

ReferenceCitation: Mohr FW, Rastan AJ, Serruys PW, Kappetein AP, Holmes DR, Pomar JL, Westaby S, Leadley K, Dawkins KD, Mack MJ. Complex coronary anatomy in coronary artery bypass graft surgery: impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years. J Thorac Cardiovasc Surg. 2011 Jan;141(1):130-40. doi: 10.1016/j.jtcvs.2010.07.094.

ReferenceCitation: Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR, Torracca L, van Es GA, Leadley K, Dawkins KD, Mohr F. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010 Jun 22;121(24):2645-53. doi: 10.1161/CIRCULATIONAHA.109.899211. Epub 2010 Jun 7.

ReferenceCitation: Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010 Mar 16;55(11):1067-75. doi: 10.1016/j.jacc.2009.09.057. Epub 2010 Jan 14.

ReferenceCitation: Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009 Mar 5;360(10):961-72. doi: 10.1056/NEJMoa0804626. Epub 2009 Feb 18. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.

lead_sponsor: Boston Scientific Corporation

location_country:
Denmark
Poland
Portugal
Spain
Italy
Austria
Latvia
Netherlands
Finland
Czech Republic
United Kingdom
Sweden
Hungary
United States
France
Belgium
Norway
Germany

location_facility: Universitatsklinik Charite Berlin, Campus Mitte

location_facility: Centre Hôpital Universitaire Sart Tilman

location_facility: University of Helsinki Meilahti Hospital

location_facility: Cardiovascular and Thoracic Surgeons of Greensboro

location_facility: Centre Hopital Universitaire Rouen - Hopital Charles Nicolle

location_facility: University Hospitals of Leicester NHS Trust Glenfield Hospital

location_facility: LeBauer Cardiovascular Research Foundation

location_facility: Charite Universitaetsmedizin Berlin, Campus Virchow Klinikum

location_facility: Institut Cardiovasculaire Paris Sud - Massy

location_facility: Campus Virchow Klinikum Herzkatheterlabor

location_facility: Erasmus MC - University Medical Center Rotterdam

location_facility: Cardiac & Vascular Research Center of Northern Michigan

location_facility: Karolinska Universitets Sjukhuset - Stockholm

location_facility: Univ. Klinik für Herzchirurgie Landeskliniken

location_facility: Oklahoma Foundation for Cardiovascular Research

location_facility: Istituto di Fisiologia Clinica, Stabilimento di Massa Ospedale

location_facility: University of Debrecen, Medical and Health Science Center

location_facility: Rockford Cardiology Research Foundation (St. Anthony's Medical Center)

location_facility: Herz- und Diabeteszentrum Nordrhein-Westfalen

location_facility: Universitätsklinikum Schleswig-Holstein Campus Kiel

location_facility: Medical University of Silesia - Katowice

intervention_type: Procedure


title: A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis

summary: This 3 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo, both in combination with methotrexate (MTX). in patients with moderate to severe active rheumatoid arthritis (RA) who currently have an inadequate response to MTX. Patients wil be randomized to receive tocilizumab 4mg/kg iv, tocilizumab 8mg/mg iv, or placebo iv, every 4 weeks; all patients will also receive methotrexate 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

ReferenceCitation: Keystone EC, Anisfeld A, Ogale S, Devenport JN, Curtis JR. Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment. J Rheumatol. 2014 Feb;41(2):216-26. doi: 10.3899/jrheum.130489. Epub 2014 Jan 15.

ReferenceCitation: Wang J, Bansal AT, Martin M, Germer S, Benayed R, Essioux L, Lee JS, Begovich A, Hemmings A, Kenwright A, Taylor KE, Upmanyu R, Cutler P, Harari O, Marchini J, Criswell LA, Platt A. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J. 2013 Jun;13(3):235-41. doi: 10.1038/tpj.2012.8. Epub 2012 Apr 10.

ReferenceCitation: Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010 Jan;62(1):33-43. doi: 10.1002/art.25053.

ReferenceCitation: Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5.

lead_sponsor: Hoffmann-La Roche

location_country: Brazil Italy Austria Australia Argentina Canada Switzerland Thailand Hungary France Israel China Singapore Mexico Germany Bulgaria Slovakia


title: A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d

summary: The primary purpose of this study is to estimate the major cytogenetic response rates of BMS-354825 and imatinib (800 mg/d) in subjects with chronic phase, Philadelphia chromosome positive, chronic myeloid leukemia (PH+ CML) with disease resistant to imatinib at a dose of 400-600 mg/d.

ReferenceType: background

ReferenceCitation: Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15;115(18):4136-47. doi: 10.1002/cncr.24504.

ReferenceCitation: Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009 Dec 3;114(24):4944-53. doi: 10.1182/blood-2009-04-214221. Epub 2009 Sep 24.

lead_sponsor: Bristol-Myers Squibb

location_country:
Spain
Italy
United Kingdom
United States
Peru
Belgium
Philippines
South Africa
Poland
Austria
Australia
Russian Federation
Argentina
Puerto Rico
Israel
Norway
Singapore
Sweden
Brazil
Canada
Switzerland
Hungary
China
Germany
Denmark
Taiwan
Ireland
Estonia
Finland
Thailand
Korea, Republic of
France


type: Other Identifier

title: Randomized, Double-Blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observation Period

summary: The primary objective of this core study was to show non-inferiority of zoledronic acid to risedronate, with respect to the proportion of patients who achieved therapeutic response. The extended observation period included participants of the core study who responded to treatment.

lead_sponsor: Novartis Pharmaceuticals

location_country:
Spain
United Kingdom
Australia
New Zealand
Canada
United States
France
South Africa
Belgium
Germany

location_facility:
Novartis Investigative Site
Novartis Investigative site


title: A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

summary: The purpose of this study is to see what effect an investigational drug (BMS-354825) has on subjects who are currently in the myeloid blast phase of chronic myeloid leukemia (CML) and who are either resistant to or intolerant of imatinib mesylate. Another purpose of the study is to see what side effects this drug may have on subjects.

design_allocation: Non-Randomized

ReferenceCitation: Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 Apr 15;109(8):3207-13. Epub 2006 Dec 21.

ReferenceCitation: Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Höglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008 Aug 15;112(4):1005-12. doi: 10.1182/blood-2008-02-140665. Epub 2008 May 13.

location_country:
Denmark
Taiwan
United Kingdom
Italy
Austria
Australia
Netherlands
Canada
Finland
Switzerland
Sweden
Philippines
Korea, Republic of
United States
France
Israel
Singapore
Belgium
Norway
Germany


title: A Phase II Study to Determine the Activity of BMS-354825 in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who Are Intolerant of Imatinib

summary: The purpose of this study is assess the effects of the investigational drug dasatinib on participants who are in chronic phase Philadelphia chromosome chronic myeloid leukemia and who are either resistant to or intolerant of imatinib. Other purposes of the study are to identify any side effects the drug may produce and to study the level of dasatanib in the blood and assess the efficacy of dasatanib in the treatment of leukemia.

ReferenceCitation: Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15;109(6):2303-9. Epub 2006 Nov 30. Erratum in: Blood. 2007 Sep 1;110(5):1438.

location_country:
Spain
Italy
United Kingdom
United States
Peru
Belgium
South Africa
Austria
Australia
Israel
Norway
Sweden
Singapore
Canada
Switzerland
Germany
Denmark
Ireland
Finland
Korea, Republic of
France
Netherlands

location_facility:
Local Institution
Local Instituion


title: A Phase II Study of BMS-354825 in Subjects With Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

summary: The purpose of this clinical research study is to learn if BMS-354825 will have activity, defined by hematologic response, in subjects who have accelerated phase chronic myeloid leukemia (CML) who are resistant to or intolerant to imatinib mesylate. The safety of this treatment will also be studied.

ReferenceCitation: Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 May 15;109(10):4143-50. Epub 2007 Jan 30.

ReferenceCitation: Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009 Jul 20;27(21):3472-9. doi: 10.1200/JCO.2007.14.3339. Epub 2009 Jun 1.

location_country:
United Kingdom
Italy
United States
Peru
Belgium
Philippines
Australia
Argentina
Israel
Norway
Sweden
Singapore
Brazil
Canada
Switzerland
Germany
Denmark
Taiwan
Finland
Thailand
Korea, Republic of
France
Netherlands


title: A Phase II Study of BMS-354825 in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

summary: The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia with primary or acquired resistance to imatinib mesylate.

ReferenceCitation: Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 1;110(7):2309-15. Epub 2007 May 11.

location_country:
Denmark
Brazil
United Kingdom
Italy
Austria
Australia
Netherlands
Argentina
Canada
Finland
Switzerland
Sweden
Korea, Republic of
United States
France
Israel
Peru
Belgium
Norway
Germany